Regeneron Trial Shows Trevogrumab Prevents Muscle Loss With GLP-1 Weight Loss
Regeneron's Phase 2 trial indicated that trevogrumab can prevent muscle loss in patients undergoing GLP-1 weight loss therapy.
Story updates
04:33:57 PM UTC
SquawkNews
By Katherine HamiltonRegeneron Pharmaceuticals reported that its drug trevogrumab prevented lean mass and muscle loss among GLP-1 users in a Phase 2 trial.The trial investigated the quality of weight loss in people living with obesity during a 52-week period.Patients who took a 75 milligram dose of…